CTOs on the Move

Mundipharma

www.mundipharma.com

 
The Mundipharma story, spanning over six decades, is one that brings together a visionary approach and a pioneering spirit – and is best told through our patients, our employees and the communities in which we serve. Our dedication to putting patients at the heart of every business decision has ensured that we continue to grow and more importantly, improve the lives of the people who need our medicines the most. That foundation has not only delivered significant results, but is a reflection of our ability to convert entrepreneurism and innovation into business success. We are focused on the transformation of ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Philippe Mazas
Chief Information Officer Profile

Similar Companies

Terumo Blood and Cell Technologies

A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.

MEDISCA

With over 25 years of experience, MEDISCA has developed a solid reputation as an innovative and entrepreneurial company in the pharmaceutical compounding industry.

Dragonfly

Dragonfly is a company that specializes in the production and distribution of cannabis products in Michigan. They offer a wide range of products including prerolls, infused prerolls, vape cartridges, and High Tide.

PamLab

Pamlab, L.L.C. is a company focused on the future. We lead the United States with use of novel folate therapies to lower homocysteine. We are looking for hard-working, motivated and optimistic individuals who would like a challenging career and are

Trimel Pharmaceuticals

Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.